Benlysta And Fampyra Fail to Make Headway As IQWiG Tightens Comparator Screw
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s health technology evaluator’s rejection of GSK’s Benlysta and Biogen Idec’s Fampyra could force companies to design separate trials for authorization and HTA assessment.